Affymetrix Boosts GeneAtlas System - Analyst Blog
16 June 2011 - 2:02AM
Zacks
Genetic products maker Affymetrix (AFFX) has
introduced a new gene expression microarray designed for use on its
coveted GeneAtlas personal microarray system. The new Human Genome
(HG)-U133+ PM Array Strip allows processing of four samples on a
single array strip at a time using the GeneAtlas system, the
industry’s first personal microarray analysis solution.
Affymetrix’s GeneAtlas platform consists of the GeneAtlas
microarray system and gene expression array plates. The GeneAtlas
system has been designed to address the need of the researchers for
an easy-to-use and affordable microarray solution for whole-genome
analysis, allowing them to have control of their samples and
expedite their pace to results and publication.
The HG-U133+ PM Array Strip leverages the knowledge acquired
from various sources such as GenBank UniGene, RefSeq and the
National Center for Biotechnology information (NCBI) to offer a
comprehensive view of the transcribed human genome (transcription
is the production of RNA copies of the DNA). It enables multiple
independent measurements per RNA transcript while offering improved
productivity and efficiency through parallel processing.
The availability of the HG-U133+ PM Array Strip on the GeneAtlas
system allows scientists to publish results more rapidly by
leveraging the most relevant whole-genome information, easy
workflow as well as high sequence coverage and data confidence.
Affymetrix, in January 2011, embarked on a pact with
Fischer Scientific Inc, a unit of Thermo Fisher
Scientific (TMO), to distribute the GeneAtlas system
across the U.S. and Canada. The agreement enables the company to
leverage Fisher Scientific’s leadership in the life sciences
industry to expand sales in research markets.
Along with Illumina Inc. (ILMN), Affymetrix is
one of the two major providers of microarray technologies primarily
used in the field of genetic research. The company holds a leading
position in the gene expression products and services market.
Affymetrix is enjoying steady end-user demand for its arrays and
is expanding its customer base through new product launches.
Moreover, the company is pursuing a number of strategies (including
expansion into new markets) aimed at expanding its top line,
representing a top priority in 2011. Its shift of focus to
high-growth markets represents a positive step for future revenue
growth.
However, Affymetrix is operating in an intensely competitive
industry and faces risks associated with lower R&D spending by
its customers, notably in Europe, due to a weak economy and
government actions (such as budget cuts). Our Neutral
recommendation on the stock is in consensus with a short-term Zacks
#3 Rank (Hold).
AFFYMETRIX INC (AFFX): Free Stock Analysis Report
ILLUMINA INC (ILMN): Free Stock Analysis Report
THERMO FISHER (TMO): Free Stock Analysis Report
Zacks Investment Research
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2023 to Aug 2024